TOP HEADLINES

Featured Story

  • Armed with 900 reps, Takeda aims for the Contrave marketing hat-trick

    With Contrave, Takeda is trying to go where no new-age weight-loss drugmakers have gone before. That means achieving the ultimate marketing goal of getting physicians to back its therapy, patients to stick with it and payers to cover it. And to help it take a shot at that trifecta, it's putting a force of 900 reps behind the drug.

First-to-market launch? Bonus--but double bonus if you're Big Pharma

When it comes to launching a next-generation drug, first is always best, right? Press releases can call it a "first-in-class" product. Sales and marketing teams can get a leg or two up on any follow-up rivals. What's not to like? McKinsey & Co. wanted to find out.

Xtandi field force gets a staffing boost for market-share battle with Zytiga

Astellas and Medivation bagged that new Xtandi approval in prostate cancer. What next? Gear up for a head-to-head with Johnson & Johnson's Zytiga. And to do that, Medivation is expanding its sales force by 50%, Medical Marketing & Media reports

AZ faces market-making task to capitalize on Movantik's edge in OIC

Congratulate AstraZeneca and Nektar Therapeutics. Their oral therapy for opioid-related constipation, Movantek, beat all rival pills to market. And if analysts are correct, that market lead will pay off big time.

Sanofi, MannKind say cutting insulin costs will make Afrezza more competitive

With an FDA approval, a partnership with Sanofi and its tiny inhaler device in hand, MannKind is gearing up to sell its Afrezza diabetes treatment in the U.S. But facing tough competitors, like Novo Nordisk's NovoLog from and Eli Lilly's Humalog, the pair are looking for whatever sales advantage they can find.

Free speech, PhRMA? Not in this off-label marketing case, feds say

The pharma industry's free speech stand in a whistleblower lawsuit against Millennium Pharmaceuticals? Not so fast, says the Department of Justice. The First Amendment doesn't protect speech that spawns illegal conduct, federal prosecutors say in their own brief in the case.

MORE NEWS